Spots Global Cancer Trial Database for Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia

Official Title: Molecular Genetic Lesions and Clinical Outcome in Pediatric ALL Patients

Study ID: NCT00003291

Conditions

Leukemia

Interventions

cytogenetic analysis

mutation analysis

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: The identification of gene mutations may allow doctors to better determine the prognosis of children with acute lymphoblastic leukemia. PURPOSE: This clinical trial is studying gene mutations to see if they are related to prognosis of cancer in children with acute lymphoblastic leukemia.

Detailed Description: OBJECTIVES: * Examine the prognostic significance of deletion of the p16 (MTS1, CDKN21) gene in children with acute lymphoblastic leukemia. * Attempt to correlate the incidence of specific, nonrandom combinations of molecular genetic lesions with clinical outcome in these patients. OUTLINE: Patients are stratified by risk (standard vs high). Bone marrow specimens from patients enrolled in CCG-1922, CCG-1882, or CCG-1901 are analyzed for the following genetic lesions: p16 deletion, p14 deletion, and p15 deletion. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment. Patients are followed for at least 3 years. PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.